HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

LFMD

LifeMD, Inc. (NASDAQ)

Healthcare — Health Information Services

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

Strong Buy 1.0 / 5 8 analysts
$3.88
$-0.21 (-5.13%)
Target: $9.88 (154.5%)
Sign in to add LFMD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$219.57M
P/E Ratio (TTM)-
Forward P/E8.82
EPS (TTM)$-0.44
Dividend Yield-
Profit Margin2.93%
Revenue Growth-1.40%
ROE-238.45%
Debt/Equity41.05
Recommendation Strong Buy 1.0
Analyst Target$9.88
Analysts8
Indexes NASDAQ

Technical Indicators

RSI (14)41.3
Beta1.99
SMA 20-
SMA 40-
52-Week High$13.09
52-Week Low$2.56
50-Day Avg$4.58
200-Day Avg$4.38
Avg Volume962.2K
Volume745.5K

Performance Analysis

NEUTRAL

LFMD presents a mixed picture with both positive and negative indicators.

~ Trading at 13% of its 52-week range.
~ RSI at 41.3 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 1.4% year-over-year.
+ Wall Street consensus is "Strong Buy" from 8 analysts.
+ Average analyst target of $9.88 implies 154.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:18 UTC

Back to Screener Export Report